Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Neurology and Therapy
|
October 31, 2025
Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations
Justin Lee, Adrian Kielhorn, Sami Fam, et al.
Annals of Clinical and Translational Neurology
|
March 11, 2026
Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD
Sean J Pittock, Jin Nakahara, Becky Parks, et al.
The Journal of Biological Chemistry
|
August 21, 2004
alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis
Yushan Wang, William Ju, Lidong Liu, et al.
The Patient
|
January 7, 2026
Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA
Justin R Abbatemarco, Adrian Kielhorn, Jeffrey C Yu, et al.
Therapeutic Advances in Neurological Disorders
|
March 19, 2021
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
Ludwig Kappos, Stanley Cohan, Douglas L Arnold, et al.
Neurology and Therapy
|
May 9, 2024
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
Stacey L Clardy, Sean J Pittock, Orhan Aktas, et al.
Journal of Neurology
|
May 27, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Neurology. Clinical Practice
|
January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Andrew Chan, John Rose, Enrique Alvarez, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Neurology and Therapy
|
October 31, 2025
Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations
Justin Lee, Adrian Kielhorn, Sami Fam, et al.
Annals of Clinical and Translational Neurology
|
March 11, 2026
Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD
Sean J Pittock, Jin Nakahara, Becky Parks, et al.
The Journal of Biological Chemistry
|
August 21, 2004
alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis
Yushan Wang, William Ju, Lidong Liu, et al.
The Patient
|
January 7, 2026
Patient Preferences for Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatments: Results from a Discrete Choice Experiment Study in the USA
Justin R Abbatemarco, Adrian Kielhorn, Jeffrey C Yu, et al.
Therapeutic Advances in Neurological Disorders
|
March 19, 2021
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
Ludwig Kappos, Stanley Cohan, Douglas L Arnold, et al.
Neurology and Therapy
|
May 9, 2024
Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
Stacey L Clardy, Sean J Pittock, Orhan Aktas, et al.
Journal of Neurology
|
May 27, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, et al.
Neurology. Clinical Practice
|
January 29, 2021
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Andrew Chan, John Rose, Enrique Alvarez, et al.
Page
of 1